29 completed, 5 unknown, 3 withdrawn, 1 active not recruiting. 19 Phase 3, 5 Phase 1, 3 Phase 4, 1 Not applicable.
By phase and status
Follow IDegLira: new trials by email Literature Review of IDegLira trials Research Report on IDegLira
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes
IDegLira - Diabetes Mellitus, Type 2 | | Withdrawn | Novo Nordisk A/S | | 2024-11-07 | 2024-10-01 |
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Insulin Degludec/liraglutide Injection, XULTOPHY® - Type 2 Diabetes | Phase 3 | Unknown | Tonghua Dongbao Pharmaceutical Co.,Ltd | 510 | 2024-08-01 | 2024-08-19 |
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
insulin degludec/liraglutide, Xultophy® - Healthy | Phase 1 | Unknown | Tonghua Dongbao Pharmaceutical Co.,Ltd | 44 | 2024-05-06 | 2024-06-10 |
The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes
IDegLira, Premixed insulin - Diabetes Mellitus, Type 2 | Phase 4 | Unknown | Peking University People's Hospital | 256 | 2024-04-30 | 2024-05-10 |
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart - Diabetes Mellitus, Type 2 Treated With Insulin | Phase 3 | Unknown | Hospital Universitario San Ignacio | 66 | 2022-12-01 | 2023-03-14 |
Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy
metformin+empagliflozin+insulin glargine, IDegLira, premixed insulin analogues - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Xiangya Hospital of Central South University | 78 | 2022-09-01 | 2022-09-19 |
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
IDegLira - Diabetes Mellitus, Type 2 | | Withdrawn | Novo Nordisk A/S | | 2022-07-30 | 2022-11-01 |
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
IDegLira - Diabetes Mellitus, Type 2 | | Completed | Novo Nordisk A/S | 175 | 2022-03-22 | 2022-11-09 |
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 |
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Xultophy® (insulin degludec/liraglutide) - Diabetes Mellitus, Type 2 | | Completed | Novo Nordisk A/S | 750 | 2021-06-02 | 2025-12-31 |
GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.
IDegLira - Diabetes Mellitus, Type 2 | | Completed | Novo Nordisk A/S | 244 | 2021-04-23 | 2025-12-31 |
Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
Insulin Degludec / Liraglutide Injectable Product, Insulin Glargine - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Palermo | 100 | 2021-04-01 | 2023-12-15 |
A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy
Insulin degludec and liraglutide (IDegLira) - Diabetes Mellitus, Type 2 | | Completed | Novo Nordisk A/S | 359 | 2020-10-21 | 2024-04-03 |
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
IDegLira, IGlarLixi, Insulin/Canaglifozin - Type 2 Diabetes | Phase 4 | Completed | University of Campania Luigi Vanvitelli | 258 | 2019-11-27 | 2020-10-22 |
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
IDegLira, insulin degludec, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Population Health Research Institute | 159 | 2019-04-23 | 2023-10-25 |
A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates
Insulin degludec/liraglutide - Diabetes Mellitus, Type 2 | | Completed | Novo Nordisk A/S | 300 | 2019-01-29 | 2021-09-22 |
IDegLira HIGH Trial
IDegLira, Insulin Degludec (U-100), Insulin Aspart - Diabetes Mellitus | Phase 3 | Completed | Emory University | 145 | 2019-01-15 | 2023-09-08 |
Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)
IDegLira - Type2 Diabetes | Not applicable | Completed | Stefano Rizza | 35 | 2018-11-19 | 2021-08-03 |
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
insulin degludec/liraglutide, insulin degludec, liraglutide - Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Completed | Novo Nordisk A/S | 24 | 2017-09-29 | 2019-11-18 |
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
insulin degludec/liraglutide - Diabetes, Diabetes Mellitus, Type 2 | | Withdrawn | Novo Nordisk A/S | | 2017-08-16 | 2017-09-05 |
Showing 20 of 38. Sign in to see all of them.
Conditions studied
Diabetes Mellitus, Type 2 (33) · Diabetes Mellitus (24) · Insulin Resistance (1) · Kidney Diseases (1)
Sponsors
Novo Nordisk A/S (27) · Tonghua Dongbao Pharmaceutical Co.,Ltd (2) · Brigham and Women's Hospital (1) · Emory University (1) · Hospital Universitario San Ignacio (1) · Peking University People's Hospital (1) · Population Health Research Institute (1) · Stefano Rizza (1) · University of Campania Luigi Vanvitelli (1) · University of Palermo (1) · Xiangya Hospital of Central South University (1)
Countries
United States (12) · Hungary (9) · Slovakia (8) · Italy (7) · Russia (7) · Germany (6) · Argentina (5) · Canada (5) · China (5) · India (5) · Mexico (5) · Spain (5) · Australia (4) · South Africa (4) · Bulgaria (3)
Top investigators
Antonino Tuttolomondo, Professor (1) · Dario Giugliano, MD (1) · Elisabetta Patorno, MD, DrPH (1) · Giuseppe Bellastella, MD, PhD (1) · Hertzel Gerstein, MD (1) · Jing Wu (1) · Katherine Esposito, MD, PhD (1) · Maria Ida Maiorino, MD, PhD (1)
Results publications
PMID 39963952, PMID 30383495, PMID 25998481, PMID 26894800, PMID 28282219, PMID 28417535, PMID 31705547, PMID 33595901, PMID 36710452, PMID 25114296, PMID 25190523, PMID 25980900, PMID 26443290, PMID 26934259, PMID 27589252, PMID 27943107, PMID 28124817, PMID 28281218, PMID 28294641, PMID 28643425, PMID 29205856, PMID 29276398, PMID 29483185, PMID 30761720, PMID 31189519, PMID 31407845, PMID 31423685, PMID 31760599, PMID 32107930, PMID 33883195, PMID 35762390, PMID 37787888, PMID 38717577, PMID 40760249
NIH funding
2014 (2), 2009 (1), 2015 (1)